Skip to content

Syncromune

3 viewers · 30d

Total raised

$144.8M

1 filing since 2024 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $144.8M
ROUNDS
1
INVESTORS
77
FOUNDED
N/A
HQ
Fort Lauderdale, FL
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Syncromune is a clinical-stage biopharmaceutical company in Fort Lauderdale, Florida developing in situ immunotherapies for incurable metastatic solid tumors. Its SYNC-T platform combines tumor cryoablation with an intratumoral multi-target biologic drug so that patient-specific tumor antigens, immunomodulatory biologics and immune cells are synchronized in tumor-draining lymph nodes to activate an anti-tumor T cell response. The lead program, SYNC-T Therapy SV-102, targets metastatic castration-resistant prostate cancer and is in the LEGION-100 Phase 2 trial after Phase 1 data reported an 87% overall response rate and 53% complete response rate. The company was founded in 2020 and has raised roughly $130M, including a $100M Series A.

What sets it apart

An entirely in situ approach: the patient's own tumor is frozen in place to release antigens and then dosed with a combination biologic, so the tumor itself acts as the vaccine rather than requiring an ex vivo manufactured cell or neoantigen product.

Funding history

1 round
EquityDec 3, 2024
Form D/A
+$144.8M$144.8M total

Latest SEC filings

via EDGAR · CIK 0001955312
Form D/A · Dec 3, 2024View on EDGAR

Products

1 tracked

SYNC-T Therapy SV-102

Clinical-stage oncology therapeutic

An investigational in situ combination immunotherapy for metastatic castration-resistant prostate cancer that pairs tumor cryoablation with an intratumoral multi-target biologic, currently in the LEGION-100 Phase 2 clinical trial.

  • Cryoablation of the tumor to release patient-specific tumor antigens in situ
  • Intratumoral multi-target immunomodulatory biologic delivered at the same session
  • Activation of anti-tumor T cell responses in tumor-draining lymph nodes
  • No ex vivo cell manufacturing or personalized neoantigen sequencing required

Links

WebsiteLinkedInSEC EDGAR filings